Business Description
Apollomics Inc
NAICS : 541714
SIC : 2834
ISIN : KYG0411D1079
Share Class Description:
APLM: Ordinary Shares - Class ATotal Employee Number:
15Description
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.1 | |||||
Equity-to-Asset | -0.48 | |||||
Debt-to-Equity | -0.2 | |||||
Debt-to-EBITDA | -0.06 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -150.08 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -35 | |||||
3-Year EPS without NRI Growth Rate | -29.9 | |||||
3-Year FCF Growth Rate | -137.2 | |||||
3-Year Book Growth Rate | 35.6 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 47.97 | |||||
9-Day RSI | 49.56 | |||||
14-Day RSI | 50.91 | |||||
3-1 Month Momentum % | 0.43 | |||||
6-1 Month Momentum % | -32.72 | |||||
12-1 Month Momentum % | 116.43 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.96 | |||||
Quick Ratio | 0.96 | |||||
Cash Ratio | 0.52 | |||||
Days Sales Outstanding | 204.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 70.1 | |||||
Shareholder Yield % | 5.29 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -108.17 | |||||
Net Margin % | -128.69 | |||||
EBITDA Margin % | -124.89 | |||||
FCF Margin % | -121.99 | |||||
OCF Margin % | -121.99 | |||||
ROE % | -1305.37 | |||||
ROA % | -106.1 | |||||
ROIC % | -537.77 | |||||
3-Year ROIIC % | -171.72 | |||||
ROC (Joel Greenblatt) % | -1431.02 | |||||
ROCE % | -484.3 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 2.4 | |||||
EV-to-EBIT | -3.5 | |||||
EV-to-Forward-EBIT | -4.28 | |||||
EV-to-EBITDA | -3.58 | |||||
EV-to-Revenue | 4.48 | |||||
EV-to-FCF | -3.67 | |||||
Earnings Yield (Greenblatt) % | -28.57 | |||||
FCF Yield % | -25.49 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:APLM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Apollomics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 8.5 | ||
| EPS (TTM) ($) | -7.57 | ||
| Beta | 2.0207 | ||
| 3-Year Sharpe Ratio | 0.04 | ||
| 3-Year Sortino Ratio | 0.13 | ||
| Volatility % | 378.08 | ||
| 14-Day RSI | 50.91 | ||
| 14-Day ATR ($) | 2.809084 | ||
| 20-Day SMA ($) | 19.5839 | ||
| 12-1 Month Momentum % | 116.43 | ||
| 52-Week Range ($) | 3.659 - 42.12 | ||
| Shares Outstanding (Mil) | 2.2 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Apollomics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Apollomics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2026 | 2026-12-22 | In 155 days | ||
| Fourth quarter earnings results for 2025 | 2026-04-27 | 13.28 (+0.32%) | ||
| Annual report for 2025 | 2026-04-24 | 13.24 (-1.36%) | ||
| Second quarter earnings results for 2025 | 2025-12-22 | 16.73 (+7.49%) | ||
| Annual report for 2024 | 2025-04-03 | 8.00 (+13.77%) | ||
| Fourth quarter earnings results for 2024 | 2025-04-03 | 8.00 (+13.77%) | ||
| 0.01:1 Stock Split | 2024-11-25 | 9.18 (-8.20%) | ||
| HC Wainwright 25th Annual Global Investment Conference | 2024-09-11 | 13.33 (-1.33%) | ||
| Canaccord Genuity 44th Annual Growth Conference | 2024-08-14 09:30 | 14.05 (-50.53%) | ||
| Second quarter earnings results for 2024 | 2024-08-14 | 14.05 (-50.53%) |
Show
Entries
Apollomics Inc Frequently Asked Questions
What is Apollomics Inc(APLM)'s stock price today?
The current price of APLM is $18.52. The 52 week high of APLM is $42.12 and 52 week low is $3.66.
When is next earnings date of Apollomics Inc(APLM)?
The next earnings date of Apollomics Inc(APLM) is 2026-12-22 Est..
Does Apollomics Inc(APLM) pay dividends? If so, how much?
Apollomics Inc(APLM) does not pay dividend.
Guru Commentaries on NAS:APLM
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Qiming Venture Partners Welcomes Apollomics' Successful IPO on Nasdaq | 2023-03-31 |
Articles on Apollomics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers